ONCAlert | Upfront Therapy for mRCC
Videos  >  

Exploring Intratumoral Immunotherapy in Melanoma and Other Malignancies

Jason Luke, MD, FACP
Published Online:10:00 PM, Fri February 7, 2020

Jason Luke, MD, FACP, associate professor of medicine in the Division of Hematology/Oncology and the director of the Cancer Immunotherapeutic Center at the UPMC Hillman Cancer Center, discusses promising clinical research around intratumoral immunotherapy.

There are multiple studies in the area of intratumoral immunotherapy that have the potential to make a large impact in the field, says Luke. One notable trail is a randomized phase III, which is evaluating tilsotolimod with or against ipilimumab (Yervoy) in patients with melanoma. If the trial is positive, it may impact the standard of car, by offering a new option for patients with melanoma who progress on a PD-1 inhibitor.

Other immunotherapy agents that can be administered intratumorally are in development and there is a need for more in-depth research that compares novel agents to the standard of care before the treatment landscape can expand.
Copyright © TargetedOnc 2020 Intellisphere, LLC. All Rights Reserved.